Market Paradox: Nektar Therapeutics’ Legal Win Against Eli Lilly Fails to Ignite Investor Confidence
This past week, the biotechnology sector witnessed a rare and counterintuitive phenomenon: a significant courtroom victory that translated into a...
lilly
Beyond Weight Loss: Eli Lilly’s Brenipatide Targets the Brain to Tackle Addiction and Mental Health
In a bold strategic pivot that underscores the pharmaceutical industry's growing fascination with incretin-based therapies, Eli Lilly and Company has...
From Fringe to Pharma: Eli Lilly’s $3.8B AtaiBeckley Acquisition Signals the Mainstreaming of Psychedelic Medicine
The pharmaceutical landscape is undergoing a profound transformation. Once relegated to the periphery of medical research and hindered by decades...
